IMGK 01
Alternative Names: 8R-70 CAR T-Cell Therapy; 8R-70 CAR-T cells; 8R-70CAR; Ex-Vivo expanded autologous IL-8 receptor modified CD70 CAR T cells; IMGK-01Latest Information Update: 23 Nov 2025
At a glance
- Originator University of Florida
- Developer Immunogenik; University of Florida
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma; Glioma
- Preclinical Brain metastases; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 23 Nov 2025 Preclinical trials in Brain metastases in USA (IV), before November 2025 (Immunogenik Pipeline, November 2025)
- 23 Nov 2025 Preclinical trials in Ovarian cancer in USA (IV), before November 2025 (Immunogenik Pipeline, November 2025)
- 23 Nov 2025 Preclinical trials in Pancreatic cancer in USA (IV), before November 2025 (Immunogenik Pipeline, November 2025)